Kornimate/medical-research-clean huggingface dataset:
effect of an internet-based dialectical behaviour therapy-informed skills training for adult drinkers

Conditions: Alcohol Drinking

Summary: 1. to determine the feasibility, acceptability, and preliminary effects of an internet-based dbt-st for reducing alcohol consumption and improving psychological distress/emotional regulation in adult drinkers 2. to explore the participants' experiences and perceptions of the proposed intervention


Eligibility criteria:
inclusion criteria: * hong kong chinese aged ≥18 * score ≥8 on the alcohol use disorders identification test * indicate psychological distress as measured by the depression, anxiety, and stress scale-21 * have an intention to stop drinking * have an electronic device and are willing to receive interventions via the internet exclusion criteria: * experiencing psychotic disorders/cognitive impairment/communication problems * participating in other alcohol abstinence/related psychosocial interventions

Keywords: dialectical behaviour therapy skills training internet-based intervention psychological distress alcohol drinking adult drinkers
cognitive rehabilitation for people with cognitive covid19

Conditions: Long Covid19

Summary: cognitive impairment is increasingly recognised as a major component of long covid, and is estimated to be present in 25-75% of affected individuals. this impairment impacts quality of life and the loss of functional ability has major consequences for affected people, their families and the wider economy given people's difficulty in returning to work. this study will focus on helping people recover from cognitive covid. this will involve use of rehabilitation strategies aimed at improving function in those cognitive functions identified in stage 1 as being most affected, and assessing the benefit of rehabilitation on quality of life and people's ability to return to everyday function. these strategies will be co-produced in collaboration with a group of people living with cognitive covid. at the end of stage 2 we will produce a freely available "covid-19 cognitive recovery guide" for affected people, their close contacts and clinicians. in conclusion, cognitive impairment is frequently observed in long covid but at present little is understood about its nature, or how it can be treated. the sheer scale of the cv19 pandemic makes this a top priority unmet need for healthcare worldwide. the aim of this study is to meet this need and to deliver a treatment plan for affected people which will help them return to normal life and working ability.


Eligibility criteria:
inclusion criteria: 1. aged between 30 and 60 years 2. evidence of prior cv19 infection: * either positive cv19 pcr * or positive cv19 antibody test * or acute symptoms consistent with the recognised core features of acute cv19 infection and post-acute symptoms consistent with the recognised core features of long covid 3. cognitive impairment persisting more than three months after the acute cv19 infection, defined in terms of subjective reports of cognitive decline post-infection exclusion criteria: 1. cognitive impairment prior to cv19 infection 2. occurrence of acute neurological disorder, such as stroke or encephalitis, that could give rise to cognitive sequelae 3. people who are on any medications that are considered by the study investigators to have significant adverse effects on cognition 4. a pre-existing major psychiatric or medical disorder that is considered by the study investigators to have potential to affect cognition 5. high alcohol intake 6. recreational drug use 7. loss of mental capacity such that the affected individual is unable to give informed consent 8. participants will not be eligible for workstream 2 if they do not exhibit significant impairment on baseline cognitive assessments, as they will not gain from cognitive rehabilitation. 9. participants with pacemakers or other implanted devices, those with metal foreign bodies (e.g. shrapnel from war injuries) and those who have had certain types of surgery will be excluded from the mri substudy. although mri is not known to affect the unborn child, we will also exclude subjects who may be pregnant just to be on the safe side.

Keywords: cognitive rehabilitation brain fog covid19
coronary artery study in pediatric heart transplantation

Conditions: Transplant Coronary Artery Disease

Summary: transplant coronary artery disease (tcad) is a significant cause of morbidity and mortality in pediatric heart transplantation (pht). understanding the pathophysiology and early detection along with attempted medical management are crucial in preventing advancement of the disease and retransplantation or mortality. coronary angiogram, although routinely used is insensitive to detect early tcad. measurement of fractional flow reserve (ffr), coronary flow reserve (cfr) and index of microvascular resistance (imr) using a doppler pressure and flow intracoronary wire may be more sensitive in evaluating the integrity of coronary vasculature and thus detect pre clinical tcad. to the best of the investigators knowledge, measurement of these parameters has not been previously reported in pht.


Eligibility criteria:
inclusion criteria: * less than 21 years and above 7 years of age exclusion criteria: * clinically significant coronary artery disease on angiography and inability to undergo ivus
assessing immune function in young patients with cytopenia that did not respond to treatment

Conditions: Dyskeratosis Congenita; Fanconi Anemia; Myelodysplastic Syndromes; Pearson Marrow-pancreas Syndrome; Shwachman-diamond Syndrome

Summary: rationale: studying biopsy, bone marrow, and blood samples from patients with cytopenia that did not respond to treatment may help doctors learn more about the disease and plan the best treatment. purpose: this laboratory study is assessing immune function in young patients with cytopenia that did not respond to treatment.

objectives: primary * to evaluate the value of tcr v beta repertoire analysis for the determination of autoimmunity in refractory cytopenia (rc). * to evaluate which immunophenotypic hematopoietic subclones are associated with oligoclonal t-cell expansion in rc. * to evaluate the presence of paroxysmal nocturnal hemoglobinuria (pnh) clones in rc. secondary * to compare the molecular response with the hematologic response in patients with rc after treatment with immunosuppressive therapy (ist). * to compare the molecular response with human leukocyte histocompatability antigen (hla) expression in patients with rc after treatment with ist. outline: this is an open-label, multicenter, nonrandomized, prospective study. patients undergo biopsy, bone marrow, and blood sample collection periodically for immunological studies. samples are analyzed for tcr v beta repertoire and paroxysmal nocturnal hemoglobinuria (pnh) clone analysis via pcr heteroduplex analysis and immunophenotyping of cd14, cd16 , cd55, cd59, and cd24 expression via flow cytometry.

Eligibility criteria:
disease characteristics: * diagnosis of refractory cytopenia (rc) including any of the following: * severe aplastic anemia (saa) * fanconi's anemia * shwachman diamond syndrome * dyskeratosis congenita * pearson syndrome * all rc patients included in the ewog mds 2006 protocol irrespective of therapy * patients who have undergone hematopoietic stem cell transplantation (hsct) may be enrolled on ewog-mds sct rc ric 06 or ewog-mds sct mds 06 protocol patient characteristics: * not specified prior concurrent therapy: * no prior immunosuppressive therapy for refractory cytopenia

Keywords: refractory cytopenia with multilineage dysplasia aplastic anemia fanconi anemia dyskeratosis congenita shwachman-diamond syndrome pearson marrow-pancreas syndrome
assessing imaging as a tool in monitoring and predicting the progression of parkinson disease

Conditions: Parkinson Disease

Summary: the purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of parkinson disease. this study will be performed in the precept cohort, an already existing cohort of 806 subjects recruited to participate in the study called, a randomized, double-blind, placebo-controlled, dose-finding study to assess the efficacy and safety of cep-1347 in patients with early parkinson's disease - (precept), sponsored by cephalon and lundbeck and coordinated by the parkinson study group. the imaging data from this long-term precept follow-up study will allow us to evaluate the long-term progression of dat loss in pd, the long-term follow-up of swedd subjects, the relationship between long-term clinical and imaging pd outcomes, and the relationship between long-term imaging outcomes and genetic and biochemical biomarkers of pd progression.

the 800 early pd subjects in this study have already been evaluated clinically and have undergone longitudinal dopamine transporter (dat) imaging with \[123i\] ß-cit (baseline and 22 months). in follow-up imaging will be performed at 24-month intervals (46 and 70 months following precept baseline). all scanning procedures will be performed at the institute for neurodegenerative disorders (ind) using methods previously employed in the precept study. subjects willing to participate will travel to new haven for their 46-month imaging visit. at ind a study coordinator and a neurologist will evaluate all subjects. the coordinator and neurologist will discuss the study procedures and evaluate the patient for eligibility. written informed consent for the study will be obtained prior to performing any study-related procedures. if eligible, participants will be injected with ß-cit and 24 hours later an imaging procedure will be used to obtain pictures of brain activity using single photon emission computed tomography (spect). this 2-day procedure will be repeated at 70 months (following precept baseline).

Eligibility criteria:
inclusion criteria: * subject was a participant in the precept clinical and imaging study * participant must be willing and able to comply with study procedures * participant must be willing and able to give informed consent. exclusion criteria: * the participant has a clinically significant clinical laboratory value and/or medical or psychiatric illness * the participant has dementia (mmse≤24) * pregnancy

Keywords: imaging parkinson progression
a real-world study of a mobile device-based serious health game on session attendance in the national diabetes prevention program

Conditions: Diabetes Mellitus Risk; Diabetes Mellitus

Summary: the overall prevalence of type 2 diabetes in the united states (us) is estimated at more than 30 million people, with an estimated 88 million more adults meeting the criteria for having prediabetes and being at risk for progressing to type 2 diabetes. the significant burden of diabetes, as well as the high individual and societal cost it bears, renders this disease among the highest public health priorities for the health authorities and policy makers. in response to the rising diabetes prevalence, the us centers for disease control and prevention (cdc) established the national diabetes prevention program (national dpp) in 2010 as a framework for diabetes prevention by providing evidence-based, affordable, and high-quality lifestyle change programs (lcps). the national dpp lcp is a yearlong education-based curriculum focused on achieving modest weight loss (5% to 7%) and increasing participants' physical activity to reduce the risk of progressing to type 2 diabetes. to ensure high-quality programs and meaningful impact on participants, the cdc sets standards for organizations that wish to offer an lcp through the diabetes prevention recognition program (dprp). the dprp plays a critical role in ensuring that organizations can effectively deliver the evidence-based lifestyle change program with quality and fidelity. to achieve recognition status, organizations must periodically provide evidence that they are following a cdc-approved curriculum and achieving meaningful results on session attendance, body weight change, and physical activity minutes. a recent analysis of national dpp data has shown that the attrition rates in this program are substantial and that they differ by age and race. moreover, the attrition rates were inversely associated with the program success, as reflected by the lcp outcomes, and, specifically, participants' weight and level of physical activity. in view of these findings, the cdc is undertaking an effort to increase participant retention in the national dpp. the proposed study will evaluate the pilot use of a free-of-charge mobile device-based serious health game (wellquest™) within the frame of the national dpp lcp. wellquest™ was designed with the goals to improve participant engagement and retention in the lcp, to encourage adoption and maintenance of healthy lifestyle habits among lcp participants, and to reinforce knowledge of the lcp curriculum.


Eligibility criteria:
inclusion criteria: * enrollment in a qualifying national dpp program * body mass index (bmi) ≥25 kg/m2 for non-asians and ≥23 kg/m2 for asians. * have prediabetes identified by either a blood test or a self-reported risk test or have a history of gestational diabetes mellitus (gdm). exclusion criteria: * participants cannot have a previous diagnosis of type 1 or type 2 diabetes, prior to enrollment in a national dpp.

Keywords: prevention serious health game
a non-interventional study of roactemra/actemra in patients with moderate to severe rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this multi-center observational study will evaluate the use of roactemra/actemra (tocilizumab) in patients with rheumatoid arthritis. eligible patients initiated on roactemra/actemra treatment according to the local label will be followed for 6 months.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * moderate to severe rheumatoid arthritis according to the revised (1987) acr criteria * patients in whom the treating physician has made the decision to commence roactemra/actemra treatment (in accordance with the local label); this can include patients who have received roactemra/actemra treatment within 8 week prior to the enrolment visit exclusion criteria: * patients who have received roactemra/actemra more than 8 weeks prior to the enrolment visit * patients who have previously received roactemra/actemra in a clinical trial or for compassionate use * treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with roactemra/actemra * history of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis
lidocaine in eras for fess

Conditions: Intraoperative Bleeding

Summary: functional endoscopic sinus surgery (fess) is a commonly performed procedure. it is known that bleeding during fess can affect directly to the visibility of safe landmarks and surgical outcomes.

functional endoscopic sinus surgery (fess) is a commonly performed procedure in the head and neck field. it is known that bleeding during fess can affect directly to the visibility of safe landmarks and surgical outcomes. use of vasoactive drugs to control bleeding is not without pitfalls. systemic effects of epinephrine may constitute a potential hazard in patients with hypertension, ischemic heart disease, anemia, preexistent liver or renal damage and endocrine dysfunction (hyperthyroidism, pheochromocytoma and diabetes mellitus). lidocaine is a prototypical local anesthetic, but it also has systemic effects that are mediated by inhibitory effects on n-methyl-d-aspartate receptors and leukocyte priming. consequently, systemic lidocaine is antiinflammatory, analgesic, and antihyperalgesic. randomized clinical trials, however, have produced mixed results. several studies have shown reduction in postoperative opioid consumption and pain scores, whereas others have failed to show a benefit.

Eligibility criteria:
inclusion criteria: * patients, 20-50 yr asa class i and ii * elective functional endoscopic sinus surgery (fess) under general anesthesia. exclusion criteria: * patient refusal, allergy to the study medication, pre-existing chronic pain at any site requiring treatment, intolerance to nonsteroidal anti-inflammatory drugs (nsaids), psychiatric or neurological disorders, seizure disorder requiring medication within the previous 2 years, body mass index \> 30 kg/ m2, revision sinus surgery, pregnancy, and patients with cardiovascular, cerebrovascular, respiratory, renal or hepatic diseases
a pilot feasibility and acceptability study of remote exercise training modalities (presto)

Conditions: Cardiovascular Diseases

Summary: this study will investigate the acceptability and efficacy of 12 weeks of: smart-device app-based (myzone) asynchronous virtual, synchronous virtual, and in-person aerobic training in individuals at risk for cardiovascular disease (cvd) who do are not meeting american heart association (aha) guidelines for physical activity. the study aims to 1) assess the effect of several approaches to remote aerobic training on measures of physical activity, cardiovascular fitness and cvd risk, and 2) quantitatively and qualitatively evaluate exercise training program fidelity, implementation, effectiveness, and remaining barriers to acceptance. participants will be asked to undergo cardiopulmonary exercise testing (cpet) before and after 12-weeks of training via one of the 4 modalities (random assignment) listed above. they will respond to questions regarding acceptability of the interventions.


Eligibility criteria:
inclusion criteria: 1. \>45 years 2. at risk for cvd (participants must have one or more of the following risk factors: hypertension, hyperlipidemia, type 2 diabetes mellitus, smoking, obesity, family history of premature cvd) 3. not meeting aha physical activity guidelines for at least 3 months prior to screening * hypertension: * systolic bp ≥140 mm hg and/or diastolic bp ≥90 mm hg and/or * use of anti-hypertensive medication * hyper / dyslipidemia * ldl cholesterol levels ≥160 mg/dl and/or * hdl cholesterol \ 150mg/dl * diabetes mellitus: * hemoglobin a1c levels ≥6.5%, fasting glucose levels ≥126 mg/dl, or 2-hour glucose levels ≥200 mg/dl after an oral glucose tolerance test and/or * use of any diabetes medication * smoking: o current regular tobacco use. * obesity: o bmi ≥30 kg/m². * family history of premature cardiovascular disease: * having a first-degree relative (parent, sibling) who developed cvd before age 55 for biological males or age 65 for biological females. exclusion criteria: 1. established diagnosis of atherosclerotic cvd 2. presence of any serious medical conditions that would not allow safe participation in exercise according to the american college of sports medicine (acsm) and the aha (56-58) 3. pregnant or anticipating pregnancy 4. plan to be away for \>2 weeks during the intervention period 5. presence of any biopsychosocial factors that the principal investigator deems as having significant potential to interfere with effective study participation
physical training introduction in lifestyle of facioscapulohumeral dystrophy patients

Conditions: Muscular Dystrophy, Facioscapulohumeral

Summary: it is now accepted that physical activity is not deleterious in myopathies, including muscular dystrophies. in patients suffering from facioscapulohumeral dystrophy (fshd), aerobic training has been reported to be associated to physiological and functional positive effects without alteration in quality of life. the review papers from van der kooi et al. (2005), cup et al. (2007) and féasson et al. (2010) suggest that the combination of endurance and strength training is even more relevant. only a few controlled and randomized studies have been conducted on this topic. the impact of such training programs on the skeletal muscle regenerative capacities has not been yet addressed. moreover, due to the fact that training programs are mainly performed on short-term supervised periods, there is a lack of knowledge regarding long-term effects, patient's autonomy and whether or not regular exercise practice can be maintained in patient's daily life. also, only a few experiments have reported an integrative view of the potential benefits of such programs on functional, biological and quality of life.

our research project aims at establishing a program of physical training that will fulfill the two following conditions: (i) being compatible with the daily professional, social and family activity of the patients so it can be integrated in their life habits and (ii) being intensive enough to induce functional benefits. this experimental work will be based on multi-factorial evaluations, i.e. biological, physiological, functional, and quality of life questionnaires. this work will be based on a collaboration between the universities of saint etienne (l. féasson), grenoble (b wuyam) and örebro (f kadi) within the rhône-alpes reference centre for rare neuromuscular diseases (jc antoine). it is accepted that exercise therapy can be recommended for patients with myopathies but long-term training load still has to be determined for each pathology. in the specific context of facioscapulohumeral dystrophy, we aim at associating the scientific evaluation of physical activity benefits and a therapeutic education of patients in order to contribute to recommendations for physicians and physiotherapists. the purpose of this study is to combine an integrated approach with a better understanding of biological process implicated in this physiological treatment strategy.

Eligibility criteria:
inclusion criteria: * facioscapulohumeral dystrophy * being capable of supporting an exercise on ergocycle * social security regimen affiliated * consent form signed exclusion criteria: * severe cardiac or respiratory insufficiency * cardiac pacemaker * morbid obesity (bmi upper to 35) * anti platelet therapy

Keywords: muscular dystrophy facioscapulohumeral physical training exercise
factors affecting hand dysfunction in patient with rheumatoid arthritis and its correlation with quality of life

Conditions: Rheumatoid Arthritis

Summary: the aims of the research are: * to predict factors affecting hand dysfunction in patient with rheumatoid arthritis * to study the effect of hand dysfunction on quality of life in patient with rheumatoid arthritis

rheumatoid arthritis (ra) is the most common chronic autoimmune systemic inflammatory arthritis, associated with considerable impairments of quality of life . hand is the principle means by which an individual interacts with people and objects in the external environment .many factors affect hand function in addition to arthritis ,. many ra patients suffer from an increased loss of muscle mass with a significant impact on these patients' quality of life , and also distal sensory, mixed sensorimotor, mononeuritis multiplex and entrapment neuropathy are the most commonly reported types of neuropathy in ra .so assessment of factors causing hand dysfunction can provide us a quick and early insight on the debilitating effects of ra on functioning and disability.thus early intervention can then be initiated which will help limit joint damage and thereby improve functional outcomes.

Eligibility criteria:
inclusion criteria: * adult patients who fulfilled the american college of rheumatology (acr) (2010) criteria for ra, attending the rheumatology and rehabilitation outpatient clinic and in-patient department, faculty of medicine, assuit university hospitals. exclusion criteria: * patients with other rheumatic diseases. * patients less than 18 years old. * patients with co-morbidities influencing disease activity and hand function (e.g., end- stage liver or renal disease, serious infections, or severe cardiac, respiratory, gastrointestinal disease) . * patient with any recent history of hand trauma, or surgery. * patient with neurological involvement as , peripheral neuropathy and radiculopathy